TXA707 is the active metabolite of TXA709 and bacterial protein FtsZ inhibitor, maintains potent activity against S. aureus strains (e.g., MRSA, VRSA, DNSSA, and LNSSA) that are resistant to current SOC antibiotics.

TPP8 is a small molecule antibacterial inhibiting the ATPase of DNA gyrase with IC50 of 0.3 uM, binds and inhibits the ATPase domain of the gyrase B subunit, shows activity against M. abscessus strains with MIC of 0.04-0.2 uM.

TBI-166 is a potential next-generation antituberculosis riminophenazine with activity against Mycobacterium tuberculosis (0.063  μg/ml).

TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria (NTM) inhibitor targeting FO-domain of F1FO-ATP synthase, shows MIC50 of 4.5 nM and 6 nM against the Mab subsp. abscessus smooth strain and rough strain respectively.

SMT-738 is a small-molecule inhibitor of bacterial lipoprotein transport complex (LolCDE), shows potent and highly selective antimicrobial activity.

SMARt751 is a small molecule that interacts with the transcriptional regulator VirS of M. tuberculosis, up-regulates expression of the mymA operon, reverses resistance to ethionamide both in vitro and in vivo.

SK-017154-O is a specific and noncompetitive inhibitor of PelA, specifically inhibits PelA esterase activity with IC50 of 11 uM, inhibits Pel-dependent PA14 biofilms with IC50 of 1.8 uM.

SF235 is a small-molecule inhibitor of macrophage infectivity potentiator (Mip) protein with IC50 and Ki 0.42 and 0.29 uM against B. pseudomallei Mip (BpMip) peptidyl-prolyl cis/trans isomerase (PPIase) activity, reduce B. pseudomallei virulence in vitro.

SAV13 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 1.06 uM in luciferase assays, reduces expression of hla and other virulence factors.

PKZ18-22 is a potency improved analog of PKZ18, inhibitiong tRNA-regulated gene expression of gram-positive bacteria, shows MIC value of 8 ug/mL against S. aureus.

OTB-658 (OTB658) is a novel oxazolidinone anti-tuberculosis agent, shows potent antibacterial activity against Mycobacterium tuberculosis, especially multi-drug resistant tuberculosis (MDR-TB) in vitro and in vivo.

NTB-3119 (NTB3119) is a novel benzothiopyranone derivative and anti-tuberculosis agent with potent in vitro activity against both drug-susceptible and drug-resistant tuberculosis clinical strains.

NSC116565 is a potent, time-dependent inhibitor of Mycobacterium tuberculosis (M.tb) ketol-acid reductoisomerase (KARI) with Ki of 95.4 nM.

ND-011992 is a cytochrome bd oxidase (Cyt-bd) inhibitor, inhibits Mycobacterium tuberculosis respiratory complex I with IC50 of 0.12 uM, targets respiratory complex I and bo3 oxidase in addition to bd-I and bd-II oxidases.

MSU-43085 is a potent, orally bioavailable inhibitor of Mycobacterium tuberculosis (Mtb, EC50=120 nM) and M. abscessus survival, targets MmpL3.

MMV652103 is an antimalarial imidazopyridazine compound, exerts potent and selective cytotoxicity in ER+ breast cancer cells, potently inhibits the oncogenic PI4KB and PIK3C2G lipid kinases with IC50 of 1.7 and 0.085 uM, respectively.

MMV1091186 (MMV 1091186) is an antimalarial compound that inhibit P. falciparum cytoplasmic isoleucyl tRNA synthetase (cIRS) with IC50 of 0.87 uM.

MD-124 is a potent antibiotic adjuvant against Gram-negative bacteria, sensitizes various Gram-negative bacterial species and strains, including multidrug resistant pathogens, toward existing antibiotics.

LPC-233 (LPC233) is a highly potent and specific inhibitor of UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC (Ki=8.9 pM), specifically inhibits lipid A synthesis and displays outstanding antibiotic activities.

KSK67 is a potent small molecule inhibitor of bacterial transcriptional activator PrfA with IC50 of 67 nM, reduces virulence factor expression in L. monocytogene.

KKL-55 is a specific small molecule inhibitor of bacterial trans-translation by binding to longation factor thermo-unstable (EF-Tu, Kd=2 uM), inhibits binding between EF-Tu and tmRNA but not between EF-Tu and tRNA, has broad-spectrum antibiotic activity.

JSF-3285 (JSF3285) is a potent small molecule inhibitor of the M. tuberculosis β-ketoacyl synthase KasA with Kd of 70.7 nM in MST assays, shows activity against H37Rv strain with MIC 0.2 uM.

JSF-3269 is a small molecule antibacterial inhibitor against Enterococcus faecium with MIC of 1.9-3.8 uM and minimal bactericidal concentration (MBC) of 7.7-15 uM.

JSF-2659 is the orally bioavailable, phosphate prodrug of JSF-2414, JSF-2659 (100 and 1 g/kg, p.o.) is highly efficacious in reducing microbial burdens in animal models of Neisseria gonorrhoeae vaginal infection as well as VRSA and C. difficile-induced co

JMV7061 (JMV-7061) is a novel potent, selective bacterial metallo-β-lactamase (MBL) inhibitor, shows submicromolar activities against VIM-type enzymes and strong NDM-1 inhibition (Ki=10-30 nM).

JBD1 is a small molecule compound that strongly inhibits biofilm formation of S. aureus, including methicillin-resistant strains, induces biofilm inhibition and metabolic remodeling through respiratory activation.

IITR06144 is a novel nitrofuran and exhibits broad-spectrum bactericidal activity against most MDR bacteria (MIC, 0.5 mg/mL).

HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL.

HR3744 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 10 uM in saeP1 promoter assays, reduces expression of hla and other virulence factors.

GSK692 (GSK-692) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=10 nM).